<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205072</url>
  </required_header>
  <id_info>
    <org_study_id>E7114</org_study_id>
    <nct_id>NCT03205072</nct_id>
  </id_info>
  <brief_title>POCS in Liver Transplantation Patients</brief_title>
  <official_title>Per-Oral Cholangioscopy in Liver Transplantation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, non-randomized, observational, consecutive case series, which
      will compare Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) and cholangioscopy with Spy
      Glass Digital System (DS) procedure at 5-10 centers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to demonstrate the clinical utility of cholangioscopy with Spy
      Glass Digital System (DS) in cadaveric donor or live donor liver transplantation patients who
      are referred for ERCP in the setting of a clinical suspicion of post liver transplant bile
      duct stricture(s). A secondary study objective is to generate a hypothesis for a randomized
      controlled trial comparing ERCP alone to ERCP with Per- Oral Cholangioscopy (POCS) in
      patients referred for ERCP post liver transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Impact of Per-Oral Cholangioscopy on Patient Management</measure>
    <time_frame>12 Months</time_frame>
    <description>To evaluate the impact of the addition of POCS to same setting ERCP on the recommended management of post-liver transplantation biliary complications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>12 Months</time_frame>
    <description>Ability to visualize the duct/lesion of interest and, if applicable, ability to obtain POCS-guided biopsy adequate for histopathology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Serious Adverse Events (SAEs) including severity, onset, time to resolution, required interventions, relatedness to endoscopic devices and/or procedures and hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of biliary re-interventions</measure>
    <time_frame>12 Months</time_frame>
    <description>Re-interventions may include but are not limited to repeat ERCP, repeat POCS, ultrasonography, stent exchanges, balloon dilations and liver biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Management</measure>
    <time_frame>3 and 12 Months</time_frame>
    <description>Confirmation at 3 months and at 12 months that recommended management at the index procedures was adequate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between endoscopic findings on POCS visualization</measure>
    <time_frame>12 Months</time_frame>
    <description>Relationship between endoscopic findings on POCS visualization during index procedure and refractory biliary strictures during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation</measure>
    <time_frame>12 Months</time_frame>
    <description>Evaluation by surgeon of whether or not POCS impacted patient management post procedure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>ERCP &amp; Spy Glass DS</arm_group_label>
    <description>Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spy Glass DS</intervention_name>
    <description>The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.</description>
    <arm_group_label>ERCP &amp; Spy Glass DS</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsies if needed at the discretion of the PI.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cadaveric donor or live donor liver transplantation patients referred for ERCP in the
        setting of a clinical suspicion of post-liver transplant bile duct stricture(s).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Liver transplantation at least 1 month prior to POCS procedure

          2. Abnormal Liver Function Tests (LFTs) and/or biliary obstructive symptoms

          3. Prior cross sectional imaging (MRI and/or US and/or CT)

          4. Suspicion of anastomotic biliary stricture(s)

          5. Diameter of bile ducts deemed sufficient to accommodate cholangioscopy system based on
             baseline imaging

          6. Willing and able to provide a written informed consent to participate in the study

          7. Willing and able to comply with study procedures and follow-up schedule

        Exclusion Criteria:

          1. Contraindication for an ERCP per local standard of practice

          2. Deemed contraindicated for POCS per local standard of practice

          3. Prior biliary treatment of biliary anastomotic stricture

          4. &lt; 18 years old

          5. Documented life expectancy of less than 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Sethi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo De Moura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Slivka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres Cardenas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan-Werner Poley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tyler Stevens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Srey Yin</last_name>
    <phone>508-683-4162</phone>
    <email>srey.yin@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York Presbyterian Hospital CUMC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amrita Sethi, MD</last_name>
      <email>as3614@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Amrita Sethi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean D Emond, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth C Verna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tyler Stevens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Prabhleen Chahal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Vargo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bijan Eghtesad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Romero-Marrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Slivka, MD</last_name>
      <email>slivkaa@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Slivka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Hughes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mordechai Rabinovitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Chennat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asif Khalid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas</name>
      <address>
        <city>São Paulo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo De Moura, MD</last_name>
      <email>eduardo.ghmoura@hc.fm.usp.br</email>
    </contact>
    <investigator>
      <last_name>Eduardo De Moura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wellington Andraus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luiz A D'Albuquerque, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mateus P Funari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomazo Franzini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vitor Brunaldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan-Werner Poley, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jan-Werner Poley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Bruno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Cardenas, MD</last_name>
      <email>acardena@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Andres Cardenas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>Per-Oral Cholangioscopy</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>Spy Glass</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

